跳至主要内容
临床试验/EUCTR2016-002180-33-PL
EUCTR2016-002180-33-PL进行中(未招募)1 期

Multiple sclerosis therapy with transdermal myelin peptide stimulation.

Centrum Neurologii Krzysztof Selmaj0 个研究点目标入组 220 人开始时间: 2016年7月14日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
220

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • The signing of informed consent to participate in the study
  • Women and men aged 18-60 years
  • RR diagnosis of MS according to the McDonald criteria 2010
  • State disability by EDSS 0 to 5.5
  • At least one relapse in the 12 months prior to screening
  • Neurologically stable during the 30 days prior to screening
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 220
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patients with diagnosis of SP MS and PP MS.
  • Pregnant patients
  • Patients with active immune system diseases, rheumatoid arthritis, scleroderma, Crohn's disease, etc.
  • Patients with bone marrow dysfunction, significant anemia, leukopenia, neutropenia, thrombocytopenia
  • Patients with active infection, bacterial, fungal or viral
  • Patients with AIDS
  • Patients with a history of syphilis, tuberculosis, hepatitis B or C
  • Patients vaccinated with a live or attenuated vaccine within 2 months prior to screening
  • Patients treatment with steroids or ACTH during the 30 days prior to screening
  • Patients treated in the past with interferon beta who discontinued treatment due to inefficiency
  • Patients with natalizumab treatment during the 6 months prior to screening
  • Patients treated with mitoxantrone 2 years before screening
  • Patients treated with fingolimod or dimethyl fumarate 2 months prior to screening
  • Patients with a history of cancer other than basal cell carcinoma
  • Patients with significant underlying cardiovascular, respiratory, gastrointestinal tract, kidney.
  • Patients who are unable to undergo MRI
  • Patients with a history of hyperactivity / allergy skin

研究者

发起方
Centrum Neurologii Krzysztof Selmaj

相似试验